Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames

Nektar/BMS said they would halt bempeg/Opdivo combination studies • Source: Alamy

Competitors developing drugs targeting interleukin-2 in oncology will have more room to potentially take the market now that one of the top programs is effectively out of the game. Nektar Therapeutics and Bristol Myers Squibb Company, who were collaborating to develop bempegaldesleukin (bempeg) in combination with the PD-1 inhibitor Opdivo (nivolumab), have called it quits, leaving only smaller partnerships for Nektar’s IL-2 therapy still active.

The companies said on 14 April they would end their clinical development program for the combination after an analysis of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.